Skip to main content
  • Home
  • Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Topic:
  • Heart Failure
  • Prevention
  • CV Renal Metabolic

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

Cardiovascular (CV) disease remains a leading cause of morbidity and mortality worldwide with heart failure increasing in prevalence. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor. The opportunity for CV disease prevention in patients with T2DM has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including many trials with SGLT2 inhibitors showing that drugs in this class cause robust reductions in heart failure. Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.  These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.   

 

This comprehensive review article aims to educate practicing cardiologists and related healthcare professionals of the latest developments in this field, and support better patient outcomes.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This review article, 'Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice' is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the PDF of the review article carefully and thoroughly, consider the learning objectives and implications, and then complete post-test questions at the end of the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if the required pass score is achieved, you will be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

This programme is intended to educate:

  • Cardiologists, heart failure specialists and other healthcare professionals who are engaged in the diagnosis and treatment of heart failure.

Learning Objectives

This review article endeavours to best address the following learning objectives:

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
Register now Log in

Speaker

Giuseppe Rosano

St George’s University Medical School of London, UK

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London where he is also the director of MSc Heart Failure. 

View full profile

David Quek

Pantai Hospital, Kuala Lumpur, Malaysia

View full profile

Felipe Martinez

National University of Cordoba, Cordoba, Argentina

Emeritus Professor of Medicine - Cordoba National University
Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina
Fellow of the European Society of Cardiology (FESC)
Fellow of the American College of Cardiology (FACC)

View full profile

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
  • 0.75 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
  • 0.50 AMA PRA Credit

Learning objectives

  • Identify patients likely to benefit from invasive procedures versus pharmacological treatment
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments
See more
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
  • 1.00 MMA

Learning objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
See more
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
  • 1.00 MMA

Learning objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
See more
A Review of Emerging ARNI Data in HFrEF
  • 1.00 EBAC

Learning objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Optimising Treatment of HF
  • 1.00 (EBAC)

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
See more
Heart Failure & Cardiomyopathy: Highlights 2019-2021
  • 0.25 AMA PRA Category 1 Credit™

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
See more